Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • Journal h-index: 24
  • Journal CiteScore: 8.01
  • Journal Impact Factor: 7.55
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Open Archive Initiative
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Scimago Journal Ranking
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page


Evaluation of Dexamethasone and Remdesivir as Potential Anti-Viral Drugs Over others for the Treatment of the COVID-19 Patients

Rashed Noor, Yusra Binte Sikandar and Syed Abdullah Ibn Asaduzzaman

Lots of research based on drug designing as well as in silico study, cell culture/animal model study, and the clinical trials are being conducted perceive the suitable therapeutic drugs and to develop vaccines in order to alleviate the ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although there are still no vaccines, some potential anti-viral drugs have been discovered of which remdesivir has been so far mostly accepted for the treatment purpose because of its multi-target actions. In addition to remdesivir, dexamethasone has been noticed with the capacity to protect the severely affected COVID-19 patients from death to some extent. Current review thus emphasized on both remdesivir and dexamethasone as the successful remedies for the ongoing pandemic; and projected on the possible mode of action of dexamethasone.